Dr. Petrylak on important updates in bladder cancer from NY GU 2022

SAP Partner | <b>Yale Medicine Urology</b>

“There are many trials that clinicians should be aware of,” says Daniel P. Petrylak, MD.

In this video, Daniel P. Petrylak, MD, PhD, discusses major takeaways and ongoing research in urothelial cancer, which was presented on at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies. Petrylak is the director of genitourinary oncology, a professor of medicine and urology, co-leader of Cancer Signaling Networks, and co-director of the Signal Transduction Program at the Yale University Cancer Center in New Haven, Connecticut.